Patents by Inventor Christoph Freiberg

Christoph Freiberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11077187
    Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 3, 2021
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Xiao-Yan Zhao, Andreas Wilmen, Christoph Freiberg, Lars Linden, Ji-Yun Kim, Subramanian Yegneswaran, Karin Regnstrom, Ursula Egner, Xinquan Wang
  • Publication number: 20200181261
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: January 29, 2020
    Publication date: June 11, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
  • Publication number: 20200157214
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: January 29, 2020
    Publication date: May 21, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
  • Patent number: 10584167
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 10, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
  • Publication number: 20180326053
    Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Application
    Filed: November 15, 2016
    Publication date: November 15, 2018
    Inventors: Xiao-Yan ZHAO, Andreas WILMEN, Christoph FREIBERG, Lars LINDEN, Ji-Yun KIM, Subramanian YEGNESWARAN, Karin REGNSTROM, Ursula EGNER, Xinquan WANG
  • Publication number: 20180162940
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: March 21, 2016
    Publication date: June 14, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
  • Patent number: 9777063
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 3, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
  • Patent number: 9649374
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 16, 2017
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Publication number: 20160319029
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 3, 2016
    Inventors: Christoph FREIBERG, Christiane OTTO, Lars LINDEN, Axel HARRENGA, Mark TRAUTWEIN, Simone GREVEN, Andreas WILMEN
  • Publication number: 20160237160
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the TWEAKR (TNFRSF12A, FN14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for us.
    Type: Application
    Filed: June 12, 2014
    Publication date: August 18, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Christian VOTSMEIER, Stefanie HAMMER, Uwe GRITZAN, Sandra BERNDT, Dmitry ZUBOV, Lars LINDEN, Sven CHRISTIAN, Axel HARRENGA, Jörg BIRKENFELD, Christoph FREIBERG, Sven GOLFIER, Andrea EICKER, Simone GREVEN, Beatrix STELTE-LUDWIG, Marian RASCHKE
  • Patent number: 9382305
    Abstract: The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 5, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Wilmen, Ulrich Haupts, Christoph Freiberg, Mark Trautwein, Lars Linden, Kirsten Leineweber, Hanna Tinel
  • Patent number: 9353186
    Abstract: The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: May 31, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
  • Patent number: 9241989
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: January 26, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Publication number: 20140187491
    Abstract: The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 3, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Wilmen, Ulrich Haupts, Christoph Freiberg, Mark Trautwein, Lars Linden, Kirsten Leineweber, Hanna Tinel
  • Publication number: 20140141003
    Abstract: The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
    Type: Application
    Filed: May 31, 2012
    Publication date: May 22, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
  • Publication number: 20130272968
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: October 17, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Publication number: 20130171147
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: July 4, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
  • Publication number: 20130129739
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: May 23, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Ottto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Publication number: 20130022606
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: January 24, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
  • Publication number: 20120321632
    Abstract: The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: December 20, 2012
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen